A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT05039515
- Locations
- 🇺🇸
University of California San Francisco (UCSF), San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04829773
- Locations
- 🇺🇸
Cambridge Ipsen US, Cambridge, Massachusetts, United States
Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04829786
Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Palovarotene Ophthalmic Solution in Healthy Adult Subjects
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04762355
- Locations
- 🇨🇦
Algorithme Pharma facility, Québec, Canada
An Efficacy and Safety Study of Palovarotene for the Treatment of MO
- Conditions
- Exostoses, Multiple Hereditary
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT03442985
- Locations
- 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇯🇵Nagoya University Hospital, Nagoya, Aiti, Japan
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 107
- Registration Number
- NCT03312634
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190, Buenos Aires, Argentina
🇬🇧Royal National Orthopaedic Hospital, Brockely Hill, Stanmore, United Kingdom
🇦🇺Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02521792
- Locations
- 🇺🇸
University of Pennsylvania, Center for Research in FOP & Related Disorders, Philadelphia, Pennsylvania, United States
🇺🇸University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco, California, United States
A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Fibrodysplasia Ossificans Progressiva
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT02322255
- Locations
- 🇦🇷
Hospital Italiano de Buenos Aires, Department of Pediatrics, Buenos Aires, Argentina
🇺🇸University of Pennsylvania, Center for FOP & Related Bone Disorders, Philadelphia, Pennsylvania, United States
🇮🇹Gaslini Institute, Unit of Rare Diseases, Department of Pediatrics, Genoa, Italy
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT02279095
- Locations
- 🇺🇸
University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco, California, United States
🇺🇸University of Pennsylvania, Center for FOP & Related Bone Disorders, Philadelphia, Pennsylvania, United States
🇫🇷Hôpital Necker-Enfants Malades, Department of Genetics, Paris, France
An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Clementia Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02190747
- Locations
- 🇺🇸
University of California San Francisco, Division of Endocrinology and Metabolism, San Francisco, California, United States
🇫🇷Hôpital Necker-Enfants Malades, Department of Genetics, Paris, France
🇬🇧The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, United Kingdom